随机对照试验与药物安全性评估。 - Suppr

Suppr

超能文献

Randomized controlled trials and assessment of drug safety.

作者信息

Clark David W J, Coulter David M, Besag Frank M C

出版信息

Drug Saf. 2008;31(12):1057-61. doi: 10.2165/0002018-200831120-00002.

DOI:10.2165/0002018-200831120-00002

PMID:19026023

Abstract

摘要

相似文献

Randomized controlled trials and assessment of drug safety.

Drug Saf. 2008;31(12):1057-61. doi: 10.2165/0002018-200831120-00002.

Institute of Medicine, Congress seek solutions to FDA's safety woes through reform, funding.

J Natl Cancer Inst. 2007 Jan 17;99(2):104-7. doi: 10.1093/jnci/djk045.

How are drugs approved? Part 1: the evolution of the Food and Drug Administration.

J Psychosoc Nurs Ment Health Serv. 2008 Jan;46(1):15-9. doi: 10.3928/02793695-20080101-06.

From the Food and Drug Administration.

JAMA. 1993 Dec 8;270(22):2669. doi: 10.1001/jama.270.22.2669.

Informatic tools and approaches in postmarketing pharmacovigilance used by FDA.

AAPS J. 2008;10(1):35-41. doi: 10.1208/s12248-007-9004-5. Epub 2008 Jan 25.

Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials.

Mayo Clin Proc. 2019 Jan;94(1):74-83. doi: 10.1016/j.mayocp.2018.07.027.

A new era in drug regulation?

Hastings Cent Rep. 2005 May-Jun;35(3):10-1.

From the Food and Drug Administration.

JAMA. 1995 Jul 26;274(4):292. doi: 10.1001/jama.274.4.292.

What's so great about newness?

Health Aff (Millwood). 2007 Nov-Dec;26(6):1793; author reply 1793-4. doi: 10.1377/hlthaff.26.6.1793.

FDA plans to continue cracking down on unapproved drugs.

Am J Health Syst Pharm. 2008 Sep 1;65(17):1594. doi: 10.2146/news080072.

引用本文的文献

Summarising the Evidence for Drug Safety: A Methodological Discussion of Different Meta-Analysis Approaches.

Drug Saf. 2017 Jul;40(7):547-558. doi: 10.1007/s40264-017-0518-1.

Review of quality assessment tools for the evaluation of pharmacoepidemiological safety studies.

BMJ Open. 2012 Sep 25;2(5). doi: 10.1136/bmjopen-2012-001362. Print 2012.

本文引用的文献

The New Zealand intensive medicines monitoring programme in pro-active safety surveillance.

Pharmacoepidemiol Drug Saf. 2000 Jul;9(4):273-80. doi: 10.1002/1099-1557(200007/08)9:4<273::AID-PDS512>3.0.CO;2-T.

Controlled trials and risk of harm.

Drug Saf. 2008;31(11):961-3. doi: 10.2165/00002018-200831110-00001.

Ezetimibe and cancer--an uncertain association.

N Engl J Med. 2008 Sep 25;359(13):1398-9. doi: 10.1056/NEJMe0807200. Epub 2008 Sep 2.

Opportunities for enhancing the FDA guidance on pharmacovigilance.

JAMA. 2008 Aug 27;300(8):952-4. doi: 10.1001/jama.300.8.952.

Prioritizing children's medicines for research: a pharmaco-epidemiological study of antiepileptic drugs.

Br J Clin Pharmacol. 2007 Jun;63(6):689-97. doi: 10.1111/j.1365-2125.2006.02842.x. Epub 2007 Jan 25.

Detection, verification, and quantification of adverse drug reactions.

BMJ. 2004 Jul 3;329(7456):44-7. doi: 10.1136/bmj.329.7456.44.

Characteristics of a unique visual field defect attributed to vigabatrin.

Epilepsia. 1999 Dec;40(12):1784-94. doi: 10.1111/j.1528-1157.1999.tb01599.x.

Practice advisory: The use of felbamate in the treatment of patients with intractable epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

Neurology. 1999 May 12;52(8):1540-5. doi: 10.1212/wnl.52.8.1540.

Making medicines safer--the need for an independent drug safety board.

N Engl J Med. 1998 Dec 17;339(25):1851-4. doi: 10.1056/NEJM199812173392512.

Prescription-event monitoring--recent progress and future horizons.

Br J Clin Pharmacol. 1998 Sep;46(3):195-201. doi: 10.1046/j.1365-2125.1998.00774.x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Randomized controlled trials and assessment of drug safety.

Drug Saf. 2008;31(12):1057-61. doi: 10.2165/0002018-200831120-00002.

Institute of Medicine, Congress seek solutions to FDA's safety woes through reform, funding.

J Natl Cancer Inst. 2007 Jan 17;99(2):104-7. doi: 10.1093/jnci/djk045.

How are drugs approved? Part 1: the evolution of the Food and Drug Administration.

J Psychosoc Nurs Ment Health Serv. 2008 Jan;46(1):15-9. doi: 10.3928/02793695-20080101-06.

From the Food and Drug Administration.

JAMA. 1993 Dec 8;270(22):2669. doi: 10.1001/jama.270.22.2669.

Informatic tools and approaches in postmarketing pharmacovigilance used by FDA.

AAPS J. 2008;10(1):35-41. doi: 10.1208/s12248-007-9004-5. Epub 2008 Jan 25.

Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials.

Mayo Clin Proc. 2019 Jan;94(1):74-83. doi: 10.1016/j.mayocp.2018.07.027.

A new era in drug regulation?

Hastings Cent Rep. 2005 May-Jun;35(3):10-1.

From the Food and Drug Administration.

JAMA. 1995 Jul 26;274(4):292. doi: 10.1001/jama.274.4.292.

What's so great about newness?

Health Aff (Millwood). 2007 Nov-Dec;26(6):1793; author reply 1793-4. doi: 10.1377/hlthaff.26.6.1793.

FDA plans to continue cracking down on unapproved drugs.

Am J Health Syst Pharm. 2008 Sep 1;65(17):1594. doi: 10.2146/news080072.

引用本文的文献

Summarising the Evidence for Drug Safety: A Methodological Discussion of Different Meta-Analysis Approaches.

Drug Saf. 2017 Jul;40(7):547-558. doi: 10.1007/s40264-017-0518-1.

Review of quality assessment tools for the evaluation of pharmacoepidemiological safety studies.

BMJ Open. 2012 Sep 25;2(5). doi: 10.1136/bmjopen-2012-001362. Print 2012.

本文引用的文献

The New Zealand intensive medicines monitoring programme in pro-active safety surveillance.

Pharmacoepidemiol Drug Saf. 2000 Jul;9(4):273-80. doi: 10.1002/1099-1557(200007/08)9:4<273::AID-PDS512>3.0.CO;2-T.

Controlled trials and risk of harm.

Drug Saf. 2008;31(11):961-3. doi: 10.2165/00002018-200831110-00001.

Ezetimibe and cancer--an uncertain association.

N Engl J Med. 2008 Sep 25;359(13):1398-9. doi: 10.1056/NEJMe0807200. Epub 2008 Sep 2.

Opportunities for enhancing the FDA guidance on pharmacovigilance.

JAMA. 2008 Aug 27;300(8):952-4. doi: 10.1001/jama.300.8.952.

Prioritizing children's medicines for research: a pharmaco-epidemiological study of antiepileptic drugs.

Br J Clin Pharmacol. 2007 Jun;63(6):689-97. doi: 10.1111/j.1365-2125.2006.02842.x. Epub 2007 Jan 25.

Detection, verification, and quantification of adverse drug reactions.

BMJ. 2004 Jul 3;329(7456):44-7. doi: 10.1136/bmj.329.7456.44.

Characteristics of a unique visual field defect attributed to vigabatrin.

Epilepsia. 1999 Dec;40(12):1784-94. doi: 10.1111/j.1528-1157.1999.tb01599.x.

Neurology. 1999 May 12;52(8):1540-5. doi: 10.1212/wnl.52.8.1540.

Making medicines safer--the need for an independent drug safety board.

N Engl J Med. 1998 Dec 17;339(25):1851-4. doi: 10.1056/NEJM199812173392512.

Prescription-event monitoring--recent progress and future horizons.

Br J Clin Pharmacol. 1998 Sep;46(3):195-201. doi: 10.1046/j.1365-2125.1998.00774.x.